MedPath

Zimberelimab

Generic Name
Zimberelimab
Drug Type
Biotech
CAS Number
2259860-24-5
Unique Ingredient Identifier
ZBL7O904IL
Indication

用于治疗二线以上复发或难治性经典型霍奇金淋巴瘤（r/r cHL）患者。

Clinical Trials
Related News

Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma

Phase 2
Not yet recruiting
Conditions
Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable
Interventions
First Posted Date
2023-10-30
Last Posted Date
2023-11-22
Lead Sponsor
Xuekui Liu
Target Recruit Count
52
Registration Number
NCT06107114
Locations
🇨🇳

Sun Yat-sen University, Guangzhou, Guangdong, China

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Phase 1
Recruiting
Conditions
Solid Tumors
Interventions
First Posted Date
2023-10-13
Last Posted Date
2025-05-15
Lead Sponsor
Gilead Sciences
Target Recruit Count
120
Registration Number
NCT06082960
Locations
🇺🇸

South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States

🇺🇸

SCRI Oncology Partners, Nashville, Tennessee, United States

🇦🇺

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

and more 3 locations

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Phase 2
Recruiting
Conditions
Locally Advanced Cervical Cancer
Interventions
First Posted Date
2023-09-28
Last Posted Date
2023-09-28
Lead Sponsor
Tang-Du Hospital
Target Recruit Count
20
Registration Number
NCT06055738
Locations
🇨🇳

Hongxi Zhao, Xi'an, Shaanxi, China

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Phase 2
Recruiting
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Radiation: Stereotactic body radiotherapy (SBRT)
Drug: Modified FOLFIRINOX
First Posted Date
2023-09-21
Last Posted Date
2025-02-13
Lead Sponsor
Gulam Manji
Target Recruit Count
60
Registration Number
NCT06048484
Locations
🇺🇸

Northwell Health R.J. Zuckerberg Cancer Center, Lake Success, New York, United States

🇺🇸

Columbia University Irving Medical Center, New York, New York, United States

🇺🇸

UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

and more 2 locations

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Phase 2
Recruiting
Conditions
Biliary Tract Carcinoma
Cholangiocarcinoma
Bile Duct Cancer
Interventions
First Posted Date
2023-09-21
Last Posted Date
2025-05-04
Lead Sponsor
Nataliya Uboha
Target Recruit Count
33
Registration Number
NCT06048133
Locations
🇺🇸

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

🇺🇸

University of Michigan Health System, Ann Arbor, Michigan, United States

🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 1 locations

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Phase 2
Not yet recruiting
Conditions
Locally Advanced Pancreatic Cancer
Interventions
Radiation: Stereotactic body radiation(SBRT)
First Posted Date
2023-08-24
Last Posted Date
2023-08-24
Lead Sponsor
Peking University Third Hospital
Target Recruit Count
96
Registration Number
NCT06009029

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Phase 2
Recruiting
Conditions
Oligometastatic Prostate Cancer
Interventions
Radiation: Stereotactic Body Radiation Therapy
First Posted Date
2023-06-23
Last Posted Date
2025-05-20
Lead Sponsor
Catherine Spina
Target Recruit Count
23
Registration Number
NCT05915442
Locations
🇺🇸

Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York, New York, United States

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Phase 1
Recruiting
Conditions
Solid Tumor
Interventions
First Posted Date
2023-06-18
Last Posted Date
2023-06-18
Lead Sponsor
Guangzhou Gloria Biosciences Co., Ltd.
Target Recruit Count
107
Registration Number
NCT05909436
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

Phase 2
Recruiting
Conditions
Classical Hodgkin Lymphoma
Interventions
First Posted Date
2023-06-13
Last Posted Date
2023-06-18
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
54
Registration Number
NCT05900765
Locations
🇨🇳

Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Phase 1
Recruiting
Conditions
Bladder Cancer
Advanced Malignancies
Head and Neck Squamous Cell Carcinoma (HNSCC)
Advanced Cancer
Esophageal Cancer
Gastric Cancer
Non-Small Cell Lung Cancer (NSCLC)
Ovarian Cancer
Renal Cell Carcinoma (RCC)
Triple Negative Breast Cancer (TNBC)
Interventions
First Posted Date
2023-06-06
Last Posted Date
2025-04-29
Lead Sponsor
Arcus Biosciences, Inc.
Target Recruit Count
87
Registration Number
NCT05891171
Locations
🇨🇳

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan

🇺🇸

Mayo Clinic Arizona, Phoenix, Arizona, United States

🇺🇸

Ronald Reagan UCLA Medical Center, Santa Monica, California, United States

and more 17 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy